The Children's Tumor Foundation (CTF) and PLOS ONE are collaborating on a new funding program in the area of neurofibromatosis (NF) research. The new initiative, called the Drug Discovery Initiative Registered Report (DDIRR) 2017 Awards, is a funder-publisher partnership to integrate the Registered Reports model in the grant application process. The request for applications for the 2017 DDIRR Awards will be open September 26th, 2017.
Registered Reports pre-determine the research question, methodology and design of a study to be carried out, and are designed to enhance the rigor, reproducibility and transparency of the science produced. Upon thorough review of the study design at the time of grant application, awardees are guaranteed an in-principle acceptance (IPA) to publication in PLOS ONE. Provided the study is conducted according to the plan, acceptance in principle is honored regardless of study outcome–as such the Registered Report model contributes to eliminate publication bias. This new award will serve as a pilot and will evolve from the Foundation's classic Drug Discovery Initiative Award program.
The new award program will work in three junctures. The first being the Preliminary Stage conducted by CTF, who will pre-select, by means of internal peer-review, those applications that will be invited to submit a full proposal in the form of a Registered Report. Following this invitation, applicants move into Stage 1. The Stage 1 process will run conjointly but independently between the Foundation and PLOS ONE using separate groups of reviewers, and will focus on evaluating the strength of the rationale and the ethics and rigor of the experimental design. Upon successful review, the CTF grant will be awarded along with a commitment to publication of the study results in PLOS ONE. When the study is completed, applicants submit their results to PLOS ONE and enter the Stage 2 review, which focuses on the adherence to the Registered Report, quality of execution, and accuracy of interpretation. Importantly, the journal commits to publish the results even if they do not support the initial hypothesis.
As this particular grant program focuses on hypothesis-testing research, it is particularly well suited for the application of Registered Reports. The process was designed to maintain independence of funding and publishing decisions while optimizing the processes, avoiding duplication and preventing research waste.
This new partnership between CTF and PLOS will bring enormous benefit to all stakeholders. A thorough review of the study design before it starts improves rigor and reproducibility and funded projects are guaranteed publication in a timely fashion, even if the results are negative – thereby eliminating publication bias and maximizing the transparency of the funded work. By securing publication before they start their research, applicants can eliminate the bias of a result-based approach.
"We are very proud to collaborate with PLOS on this innovative model, which will guarantee timely dissemination of results and data of the Children's Tumor Foundation's Drug Discovery Initiative Registered Report projects", said Salvatore La Rosa, Ph.D., Vice President of Research and Development for the Children's Tumor Foundation. "This will translate into acceleration towards more transparent and reproducible science for the NF research community."
"Registered Reports have an enormous potential to improve rigor and combat publication bias," said Joerg Heber, PhD, Editor-in-Chief, PLOS ONE. "We are delighted to collaborate with the Children Tumor Foundation to experiment with their integration in the grant application process and therefore provide incentives for their adoption."
###
CONTACT:
Rebecca Harris
Public Relations Manager
Children's Tumor Foundation
[email protected] | 646.738.8563
David Knutson
Sr. Manager, Communications, PLOS
[email protected] Direct +1 415-568-4524 I Cell +1 651-260-8288
ABOUT THE CHILDREN'S TUMOR FOUNDATION:
The Children's Tumor Foundation is a 501(c)(3) not-for-profit organization dedicated to funding and driving innovative research that will result in effective treatments for the millions of people worldwide living with neurofibromatosis (NF), a term for three distinct disorders: NF1, NF2, and schwannomatosis. NF causes tumors to grow on nerves throughout the body and may lead to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, and cancer. NF affects 1 in every 3,000 births across all populations equally. There is no cure yet – but the Children's Tumor Foundation mission of driving research, expanding knowledge, and advancing care for the NF community fosters our vision of one day ending NF. For more information, please visit http://www.ctf.org.
ABOUT PLOS
PLOS ONE is published by PLOS, a nonprofit publisher and advocacy organization founded to accelerate progress in science and medicine by leading a transformation in research communication.
Media Contact
David Knutson
[email protected]
